Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

Abstract

Purpose In the critically ill, hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality. Granular data are required for optimizing management, and developing guidelines and clinical trials. Methods We carried out a prospective international cohort study of adult patients (≥ 18 years of age) with HA-BSI treated in intensive care units (ICUs) between June 2019 and February 2021. Results 2600 patients from 333 ICUs in 52 countries were included. 78% HA-BSI were ICU-acquired. Median Sequential Organ Failure Assessment (SOFA) score was 8 [IQR 5; 11] at HA-BSI diagnosis. Most frequent sources of infection included pneumonia (26.7%) and intravascular catheters (26.4%). Most frequent pathogens were Gram-negative bacteria (59.0%), predominantly Klebsiella spp. (27.9%), Acinetobacter spp . (20.3%), Escherichia coli (15.8%), and Pseudomonas spp . (14.3%). Carbapenem resistance was present in 37.8%, 84.6%, 7.4%, and 33.2%, respectively. Difficult-to-treat resistance (DTR) was present in 23.5% and pan-drug resistance in 1.5%. Antimicrobial therapy was deemed adequate within 24 h for 51.5%. Antimicrobial resistance was associated with longer delays to adequate antimicrobial therapy. Source control was needed in 52.5% but not achieved in 18.2%. Mortality was 37.1%, and only 16.1% had been discharged alive from hospital by day-28. Conclusions HA-BSI was frequently caused by Gram-negative, carbapenem-resistant and DTR pathogens. Antimicrobial resistance led to delays in adequate antimicrobial therapy. Mortality was high, and at day-28 only a minority of the patients were discharged alive from the hospital. Prevention of antimicrobial resistance and focusing on adequate antimicrobial therapy and source control are important to optimize patient management and outcomes. Supplementary Information The online version contains supplementary material available at 10.1007/s00134-022-06944-2.

Mortality Due to Multidrug-Resistant Gram-Negative Bacteremia in an Endemic Region: No Better Than a Toss of a Coin

“…Delayed adequate antimicrobial therapy was not associated with 28-day mortality. Such observation may be impacted by several confounders and should be interpreted with caution, as also underlined by other larger studies [40]. Limited data report adequate antibiotic therapy in ICU patients with MDR bacteria.…”

Rationale and clinical application of antimicrobial stewardship principles in the intensive care unit: a multidisciplinary statement

“…Infections sustained by multidrug-resistant bacteria (MDRO) increase the severity of infectious complications, negatively affecting morbidity, mortality, and care costs [8,9].…”

Implementation Strategies for Preventing Healthcare-Associated Infections across the Surgical Pathway: An Italian Multisociety Document

“…Recently, the results of a prospective international cohort study including adult patients with hospital-acquired bloodstream infections managed in ICUs from June 2019 to February 2021 (EUROBACT-2 international cohort study) [ 10 ] were published. Hospital-acquired bloodstream infections were most frequently caused by Gram-negative bacteria, including carbapenem-resistant and difficult-to-treat bacteria.…”